Eidos Therapeutics to Present Data on its Potential Treatment for Transthyretin Amyloidosis at the American Heart Association

PALO ALTO, Calif., Nov. 9, 2017 /PRNewswire/ -- Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced two upcoming oral presentations regarding AG10, its therapeutic candidate for transthyretin amyloidosis, at the American Heart Association's (AHA) 2017 Annual Scientific Sessions.

Uma Sinha, Ph.D., Eidos' chief scientific officer, will present an abstract entitled "AG10 Potently and Selectively Stabilizes Transthyretin in vitro and Upon Oral Dosing in Dogs: Potential for Treating Transthyretin Amyloidosis" on Tuesday, Nov 14 at 2:00 PM.

Isabella Graef, M.D., Eidos' co-founder and assistant professor of pathology at Stanford University, will present an abstract entitled "AG10 Stabilizes Pathogenic TTR Variants With High Potency - Potential for an Effective Treatment for ATTR Cardiomyopathy" on Tuesday, Nov 14 at 5:45 PM.

About AG10
AG10 is a small molecule that selectively and potently binds to and stabilizes the tetrameric protein transthyretin, preventing its dissociation into disease-causing monomers. AG10 was discovered and initially developed by Isabella Graef, MD and Mamoun Alhamadsheh, PhD, at Stanford University and the University of the Pacific, respectively.

About transthyretin amyloid cardiomyopathy (ATTR-CM)
ATTR-CM is a progressive, fatal disease caused by the accumulation of misfolded ATTR fibrils in the heart. These deposits are toxic to cardiac muscle cells and limit the heart's ability to fill completely during relaxation, leading to progressive and fatal heart failure.

Approximately 240,000 people worldwide suffer from ATTR cardiomyopathy, though the patient population may be underestimated due to its rarity and confusion with more common forms of heart failure. Most patients are diagnosed after age 60, when the disease is already advanced, and may progress rapidly.

Some patients are predisposed to ATTR cardiomyopathy due to mutations in the gene that encodes TTR. The most prevalent pathogenic mutation, V122I TTR, is carried by 3.4% of African Americans.

There are no FDA-approved medications indicated for the treatment of ATTR cardiomyopathy.

About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company based in the San Francisco Bay Area. Eidos is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company's singular mission is to improve the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanford's TRAM and SPARK programs, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

About BridgeBio Pharma
BridgeBio is a clinical-stage biotechnology company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat rare diseases at their source.

Founded in 2015 by a team of industry veterans who previously brought more than a dozen products to market, BridgeBio has built a portfolio of ten transformative drug programs that address rare diseases across oncology, cardiology, dermatology and endocrinology. The drugs are in various phases of development, from discovery to late clinical stage.

With a commitment to scientific excellence and rapid execution, BridgeBio aims to translate today's discoveries into tomorrow's medicines.

SOURCE Eidos Therapeutics